{
  "legislationId": "119_HR_8205",
  "lastUpdate": "2026-04-15T11:39:04.026Z",
  "history": [
    {
      "timestamp": "2026-04-15T11:39:04.026Z",
      "source_url": "https://www.congress.gov/119/bills/hr8205/BILLS-119hr8205ih.htm",
      "model": "gemini-flash-lite-latest",
      "prompt_sent": "\nROLE: Fact Checker.\nZADANIE: Porównaj SOURCE (oryginał) i SUMMARY (streszczenie przygotowane przez inne AI).\n\nTwoim celem jest wykrycie \"ZMYŚLONYCH KONKRETÓW\" (Fabricated Entities) w SUMMARY.\n\nSOURCE:\n[Congressional Bills 119th Congress] [From the U.S. Government Publishing Office] [H.R. 8205 Introduced in House (IH)] <DOC> 119th CONGRESS 2d Session H. R. 8205 To amend the Accelerating Access to Critical Therapies for ALS Act to reauthorize the provisions of such Act through fiscal year 2031, and for other purposes. _______________________________________________________________________ IN THE HOUSE OF REPRESENTATIVES April 6, 2026 Mr. Quigley (for himself and Mr. Calvert) introduced the following bill; which was referred to the Committee on Energy and Commerce _______________________________________________________________________ A BILL To amend the Accelerating Access to Critical Therapies for ALS Act to reauthorize the provisions of such Act through fiscal year 2031, and for other purposes. Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled, SECTION 1. SHORT TITLE. This Act may be cited as the ``Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026''. SEC. 2. REAUTHORIZATION OF ACCELERATING ACCESS TO CRITICAL THERAPIES FOR ALS ACT. (a) In General.--Section 7 of the Accelerating Access to Critical Therapies for ALS Act (Public Law 117-79) is amended by striking ``2026'' and inserting ``2031''. (b) Grants for ALS Research.--Section 2(f) of the Accelerating Access to Critical Therapies for ALS Act (21 U.S.C. 360ee note) is amended by striking ``2026'' and inserting ``2031''. (c) Sense of Congress.--The Committee on Energy and Commerce of the House of Representatives expresses support for directly appropriating funds to carry out each section of the Accelerating Access to Critical Therapies for ALS Act (Public Law 117-79). SEC. 3. IMPROVEMENTS TO PROGRAM FOR GRANTS FOR RESEARCH ON THERAPIES FOR ALS. (a) Clinical Trial Status Review.--Section 2(b) of the Accelerating Access to Critical Therapies for ALS Act (21 U.S.C. 360ee note) is amended by adding at the end the following: ``(4) Clinical trial status review.-- ``(A) In general.--In reviewing applications for renewals of a grant awarded under this section with respect to an investigational drug, the Secretary shall assess the status of a clinical trial carried out for such drug with respect to data on enrollment of patients in such clinical trial. ``(B) Interim clinical trial data.--To enable the Secretary to make the assessment under subparagraph (A) with respect to an investigational drug, the Secretary shall request that the manufacturer of the investigational drug share interim clinical trial data with respect to such drug with the Secretary.''. (b) Clarifying Participating Clinical Trial Definition.--Section 2(e) of the Accelerating Access to Critical Therapies for ALS Act (21 U.S.C. 360ee note) is amended by adding at the end the following: ``(4) The term `phase 3', with respect to a clinical trial, includes a phase 2/3 combined trial and a planned phase 3 clinical trial that is not yet enrolling participants.''. SEC. 4. REPORT ON ALS AND OTHER RARE NEURODEGENERATIVE DISEASE ACTION PLANS. Section 4 of the Accelerating Access to Critical Therapies for ALS Act (21 U.S.C. 360aa note) is amended by adding at the end the following: ``(c) Report on ALS and Other Rare Neurodegenerative Disease Action Plans.--Not later than one year after the date of enactment of the Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026, the Commissioner of Food and Drugs shall publish on the website of the Food and Drug Administration a report that contains-- ``(1) an updated action plan, including-- ``(A) a description of the actions the Food and Drug Administration intends to take during the 5-year period following publication of the plan with respect to the program enhancements, policy development, regulatory science initiatives, and other appropriate initiatives described in subsection (a); ``(B) a description of the resources necessary to implement each section of the plan within such 5-year period; and ``(C) specific approaches the Commissioner will take to improve coordination of implementation of the plan with rare neurodegenerative disease communities that are not specifically ALS communities; and ``(2) with respect to the Action Plan for Rare Neurodegenerative Diseases including Amyotrophic Lateral Sclerosis (ALS) published by the Food and Drug Administration on June 23, 2022 (referred to in this section as the `2022 Action Plan'), a description of-- ``(A) the actions taken by the Food and Drug Administration under the 2022 Action Plan; ``(B) the effect of the implementation of the 2022 Action Plan on the development of therapies and regulatory consideration of therapies for ALS and other rare neurodegenerative diseases; ``(C) any programs and initiatives that established or carried out as part of the implementation of the 2022 Action Plan; and ``(D) the extent to which the 2022 Action Plan was implemented with respect to rare neurodegenerative diseases that are not amyotrophic lateral sclerosis.''. SEC. 5. GAO REPORT. Not later than 4 years after the date of enactment of this Act, the Comptroller General of the United States shall submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate a report containing the analyses and data described in section 6 of the Accelerating Access to Critical Therapies for ALS Act (Public Law 117- 79) (as in effect on the date of enactment of this Act). <all>\n\nSUMMARY TO EVALUATE:\nTitle: Extending Access to Critical ALS Therapies and Research Through 2031\nSummary: This bill extends funding and support for ALS research and access to experimental treatments for another five years. It aims to speed up the development of new therapies for patients with ALS and other rare brain diseases.\nKey Points: Extends ALS research grants and programs until 2031., Requires drug makers to share early trial data to monitor progress., Updates the definition of clinical trials to include more types of studies., Mandates a new FDA action plan for rare neurodegenerative diseases.\n\nZASADY OCENY:\n1. Sprawdź wszystkie LICZBY, DATY i KWOTY w SUMMARY. Jeśli którejś brakuje w SOURCE -> is_valid: false.\n2. Sprawdź wszystkie NAZWISKA, ORGANIZACJE i MIEJSCA w SUMMARY. Jeśli którejś brakuje w SOURCE -> is_valid: false.\n3. Sprawdź wszystkie konkretne DZIAŁANIA PRAWNE . Jeśli tego mechanizmu nie ma w SOURCE -> is_valid: false.\n\nWAŻNE: Abstrakcyjne pojęcia (np. \"transparentność\", \"zaufanie\") są dozwolone jako wnioski.\n\nOUTPUT (JSON):\n{\n  \"is_valid\": true/false,\n  \"issue\": \"fabricated_entity\" / \"contradiction\" / \"none\"\n}\n\nWYMAGANIA FORMATOWANIA:\n1. Odpowiedz WYŁĄCZNIE surowym obiektem JSON.\n2. NIE używaj bloków kodu Markdown.\n3. NIE dodawaj żadnych wstępów ani wyjaśnień przed ani po JSONie.\n4. JSON musi być poprawny i gotowy do parsowania.\n\n",
      "ai_response_raw": "{\n  \"is_valid\": true,\n  \"issue\": \"none\"\n}"
    },
    {
      "timestamp": "2026-04-15T11:22:16.465Z",
      "source_url": "https://www.congress.gov/119/bills/hr8205/BILLS-119hr8205ih.htm",
      "model": "gemini-flash-latest",
      "prompt_sent": "\nJesteś ekspertem od prawa Stanów Zjednoczonych, który ma za zadanie analizować dokumenty ustaw, uchwał oraz innych dokumentów legislacyjnych, a następnie przygotowywać z nich informacje w przystępny sposób dla obywateli. Twoim celem jest przedstawienie informacji tak, aby obywatele mogli sami ocenić wpływ legislacji na ich życie, nawet bez posiadania specjalistycznej wiedzy legislacyjnej. Skup się na faktach i obiektywnych skutkach wprowadzanych zmian, unikając wartościowania i osobistych opinii. Wszelki żargon prawny jest zabroniony. Prezentuj informacje w jasny, zwięzły i angażujący sposób, tak aby były zrozumiałe dla osoby bez wykształcenia prawniczego. Unikaj długich, złożonych zdań. Zamiast pisać \"projekt ma na celu nowelizację kodeksu podatkowego...\", napisz \"Zmiany w podatkach: nowe ulgi i obowiązki dla...\". Kontynuuj swoją pracę, dopóki nie rozwiążesz swojego zadania. Jeśli nie masz pewności co do generowanej treści, przeanalizuj dokument ponownie – nie zgaduj. Rozplanuj dobrze swoje zadanie przed przystąpieniem do niego. W podsumowaniu i kluczowych punktach, jeśli to możliwe i uzasadnione, podkreśl, jakie konkretne korzyści lub skutki (pozytywne lub negatywne) wprowadza ustawa dla życia codziennego obywateli, ich praw i obowiązków, finansów osobistych, bezpieczeństwa i innych ważnych kwestii (np. kategorycznych zakazów i nakazów czy najważniejszych konkretnych alokacji finansowych i terytorialnych).\n\nTwoja odpowiedź MUSI być w formacie JSON - i zawierać następujące klucze.\nZanim zwrócisz odpowiedź, dokładnie zweryfikuj, czy cała struktura JSON jest w 100% poprawna, włącznie ze wszystkimi przecinkami, nawiasami klamrowymi, kwadratowymi oraz cudzysłowami. Błędny JSON jest nieakceptowalny i uniemożliwi przetworzenie Twojej pracy.\n\nPrzeanalizuj dokładnie poniższy tekst dokumentu prawnego. To jest treść, na podstawie której masz wygenerować podsumowanie i kluczowe punkty:\n--- POCZĄTEK DOKUMENTU ---\n[Congressional Bills 119th Congress] [From the U.S. Government Publishing Office] [H.R. 8205 Introduced in House (IH)] <DOC> 119th CONGRESS 2d Session H. R. 8205 To amend the Accelerating Access to Critical Therapies for ALS Act to reauthorize the provisions of such Act through fiscal year 2031, and for other purposes. _______________________________________________________________________ IN THE HOUSE OF REPRESENTATIVES April 6, 2026 Mr. Quigley (for himself and Mr. Calvert) introduced the following bill; which was referred to the Committee on Energy and Commerce _______________________________________________________________________ A BILL To amend the Accelerating Access to Critical Therapies for ALS Act to reauthorize the provisions of such Act through fiscal year 2031, and for other purposes. Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled, SECTION 1. SHORT TITLE. This Act may be cited as the ``Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026''. SEC. 2. REAUTHORIZATION OF ACCELERATING ACCESS TO CRITICAL THERAPIES FOR ALS ACT. (a) In General.--Section 7 of the Accelerating Access to Critical Therapies for ALS Act (Public Law 117-79) is amended by striking ``2026'' and inserting ``2031''. (b) Grants for ALS Research.--Section 2(f) of the Accelerating Access to Critical Therapies for ALS Act (21 U.S.C. 360ee note) is amended by striking ``2026'' and inserting ``2031''. (c) Sense of Congress.--The Committee on Energy and Commerce of the House of Representatives expresses support for directly appropriating funds to carry out each section of the Accelerating Access to Critical Therapies for ALS Act (Public Law 117-79). SEC. 3. IMPROVEMENTS TO PROGRAM FOR GRANTS FOR RESEARCH ON THERAPIES FOR ALS. (a) Clinical Trial Status Review.--Section 2(b) of the Accelerating Access to Critical Therapies for ALS Act (21 U.S.C. 360ee note) is amended by adding at the end the following: ``(4) Clinical trial status review.-- ``(A) In general.--In reviewing applications for renewals of a grant awarded under this section with respect to an investigational drug, the Secretary shall assess the status of a clinical trial carried out for such drug with respect to data on enrollment of patients in such clinical trial. ``(B) Interim clinical trial data.--To enable the Secretary to make the assessment under subparagraph (A) with respect to an investigational drug, the Secretary shall request that the manufacturer of the investigational drug share interim clinical trial data with respect to such drug with the Secretary.''. (b) Clarifying Participating Clinical Trial Definition.--Section 2(e) of the Accelerating Access to Critical Therapies for ALS Act (21 U.S.C. 360ee note) is amended by adding at the end the following: ``(4) The term `phase 3', with respect to a clinical trial, includes a phase 2/3 combined trial and a planned phase 3 clinical trial that is not yet enrolling participants.''. SEC. 4. REPORT ON ALS AND OTHER RARE NEURODEGENERATIVE DISEASE ACTION PLANS. Section 4 of the Accelerating Access to Critical Therapies for ALS Act (21 U.S.C. 360aa note) is amended by adding at the end the following: ``(c) Report on ALS and Other Rare Neurodegenerative Disease Action Plans.--Not later than one year after the date of enactment of the Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026, the Commissioner of Food and Drugs shall publish on the website of the Food and Drug Administration a report that contains-- ``(1) an updated action plan, including-- ``(A) a description of the actions the Food and Drug Administration intends to take during the 5-year period following publication of the plan with respect to the program enhancements, policy development, regulatory science initiatives, and other appropriate initiatives described in subsection (a); ``(B) a description of the resources necessary to implement each section of the plan within such 5-year period; and ``(C) specific approaches the Commissioner will take to improve coordination of implementation of the plan with rare neurodegenerative disease communities that are not specifically ALS communities; and ``(2) with respect to the Action Plan for Rare Neurodegenerative Diseases including Amyotrophic Lateral Sclerosis (ALS) published by the Food and Drug Administration on June 23, 2022 (referred to in this section as the `2022 Action Plan'), a description of-- ``(A) the actions taken by the Food and Drug Administration under the 2022 Action Plan; ``(B) the effect of the implementation of the 2022 Action Plan on the development of therapies and regulatory consideration of therapies for ALS and other rare neurodegenerative diseases; ``(C) any programs and initiatives that established or carried out as part of the implementation of the 2022 Action Plan; and ``(D) the extent to which the 2022 Action Plan was implemented with respect to rare neurodegenerative diseases that are not amyotrophic lateral sclerosis.''. SEC. 5. GAO REPORT. Not later than 4 years after the date of enactment of this Act, the Comptroller General of the United States shall submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate a report containing the analyses and data described in section 6 of the Accelerating Access to Critical Therapies for ALS Act (Public Law 117- 79) (as in effect on the date of enactment of this Act). <all>\n--- KONIEC DOKUMENTU ---\n\nPAMIĘTAJ: Twoja odpowiedź MUSI być wyłącznie poprawnym obiektem JSON. Nie dodawaj żadnych dodatkowych znaków, komentarzy ani tekstu przed znacznikiem '{' ani po znaczniku '}'. Cała odpowiedź musi być parsowalna jako JSON.\nNa podstawie POWYŻSZEGO dokumentu, wypełnij poniższą strukturę JSON:\nOto struktura JSON, której oczekuję (wypełnij ją treścią):\n{\n  \"pl_ai_title\": \"Nowy, krótki tytuł dla aktu prawnego po polsku, oddający sedno wprowadzanych zmian (np. maksymalnie 10-12 słów).\",\n  \"pl_summary\": \"2-3 zdania zwięzłego podsumowania treści aktu prawnego po polsku, napisane z perspektywy wpływu na życie codzienne obywateli.\",\n  \"pl_key_points\": [\n    \"Pierwszy krótki punkt po polsku dotyczący najważniejszych wprowadzanych rozwiązań lub zmian.\",\n    \"Drugi krótki punkt po polsku...\"\n  ],\n  \"eng_ai_title\": \"A new, short title for the legal act in English, capturing the essence of the changes (e.g., max 10-12 words).\",\n  \"eng_summary\": \"2-3 sentences summarizing the legal act in English, from the perspective of its impact on citizens' daily lives.\",\n  \"eng_key_points\": [\n    \"First short bullet point in English regarding the most important solutions or changes being introduced.\",\n    \"Second short bullet point in English...\"\n  ],\n  \"de_ai_title\": \"Ein neuer, kurzer Titel für das Rechtsdokument auf Deutsch, der den Kern der Änderungen erfasst (z.B. max. 10-12 Wörter).\",\n  \"de_summary\": \"2-3 Sätze Zusammenfassung des Rechtsdokuments auf Deutsch, aus der Perspektive seiner Auswirkungen auf das tägliche Leben der Bürger.\",\n  \"de_key_points\": [\n    \"Erster kurzer Stichpunkt auf Deutsch zu den wichtigsten eingeführten Lösungen oder Änderungen.\",\n    \"Zweiter kurzer Stichpunkt auf Deutsch...\"\n  ],\n  \"fr_ai_title\": \"Un nouveau titre court pour l'acte juridique en français, saisissant l'essence des changements (par exemple, 10-12 mots maximum).\",\n  \"fr_summary\": \"Résumé de 2-3 phrases de l'acte juridique en français, du point de vue de son impact sur la vie quotidienne des citoyens.\",\n  \"fr_key_points\": [\n    \"Premier court point en français concernant les solutions ou changements les plus importants introduits.\",\n    \"Deuxième court point en français...\"\n  ],\n  \"es_ai_title\": \"Un nuevo título breve para el acto jurídico en español, que recoja la esencia de los cambios (por ejemplo, máximo 10-12 palabras).\",\n  \"es_summary\": \"Resumen de 2-3 frases del acto jurídico en español, desde la perspectiva de su impacto en la vida cotidiana de los ciudadanos.\",\n  \"es_key_points\": [\n    \"Primer punto breve en español sobre las soluciones o cambios más importantes que se introducen.\",\n    \"Segundo punto breve en español...\"\n  ],\n  \"it_ai_title\": \"Un nuovo titolo breve per l'atto giuridico in italiano, che colga l'essenza delle modifiche (ad es. massimo 10-12 parole).\",\n  \"it_summary\": \"Riepilogo di 2-3 frasi dell'atto giuridico in italiano, dal punto di vista del suo impatto sulla vita quotidiana dei cittadini.\",\n  \"it_key_points\": [\n    \"Primo breve punto in italiano riguardante le soluzioni o le modifiche più importanti introdotte.\",\n    \"Secondo breve punto in italiano...\"\n  ],\n  \"nl_ai_title\": \"Een nieuwe, korte titel voor de rechtshandeling in het Nederlands, die de essentie van de wijzigingen weergeeft (bijv. max. 10-12 woorden).\",\n  \"nl_summary\": \"Samenvatting van 2-3 zinnen van de rechtshandeling in het Nederlands, vanuit het perspectief van de impact op het dagelijks leven van burgers.\",\n  \"nl_key_points\": [\n    \"Eerste korte punt in het Nederlands betreffende de belangrijkste geïntroduceerde oplossingen of wijzigingen.\",\n    \"Tweede korte punt in het Nederlands...\"\n  ],\n  \"pt_ai_title\": \"Um novo título curto para o ato jurídico em português, capturando a essência das mudanças (por exemplo, máx. 10-12 palavras).\",\n  \"pt_summary\": \"Resumo de 2-3 frases do ato jurídico em português, na perspetiva do seu impacto na vida quotidiana dos cidadãos.\",\n  \"pt_key_points\": [\n    \"Primeiro ponto curto em português sobre as soluções ou alterações mais importantes introduzidas.\",\n    \"Segundo ponto curto em português...\"\n  ],\n  \"category\": [\"Categorize the document into one category by default, based on the field it primarily concerns. Choose up to 3 if the document also touches upon SIGNIFICANT issues from other categories. You MUST select categories ONLY from the following list: Health, Education, Family, Taxes, Labor, Security, Environment, Courts and Law, Transport, Benefits, Real Estate, Media and Culture, Local Government, Migration, Agriculture, Public Investments, Informatization, Economy. If the document does not definitively fit any of these, you MUST use \"Other\". If you use \"Other\", it should be the ONLY category selected. Do NOT invent new categories. The response must be an array of strings, e.g., [\"Taxes\", \"Family\"].\"]\n}\n\n",
      "ai_response_raw": "{\n  \"pl_ai_title\": \"Przedłużenie wsparcia w dostępie do nowoczesnych terapii na ALS do 2031 roku\",\n  \"pl_summary\": \"Ustawa przedłuża finansowanie badań i ułatwia dostęp do nowych leków dla osób cierpiących na stwardnienie zanikowe boczne (ALS) oraz inne rzadkie choroby układu nerwowego. Dzięki nowym przepisom pacjenci zyskają dłuższą perspektywę wsparcia finansowego na leczenie eksperymentalne.\",\n  \"pl_key_points\": [\n    \"Przedłużenie programu grantów na badania nad ALS do 2031 roku.\",\n    \"Lepszy nadzór nad postępami w badaniach klinicznych i rekrutacją pacjentów.\",\n    \"Rozszerzenie definicji badań klinicznych, co przyspieszy dostęp do nowych terapii.\",\n    \"Obowiązek publikacji planu działania FDA dla rzadkich chorób neurodegeneracyjnych.\"\n  ],\n  \"eng_ai_title\": \"Extending Access to Critical ALS Therapies and Research Through 2031\",\n  \"eng_summary\": \"This bill extends funding and support for ALS research and access to experimental treatments for another five years. It aims to speed up the development of new therapies for patients with ALS and other rare brain diseases.\",\n  \"eng_key_points\": [\n    \"Extends ALS research grants and programs until 2031.\",\n    \"Requires drug makers to share early trial data to monitor progress.\",\n    \"Updates the definition of clinical trials to include more types of studies.\",\n    \"Mandates a new FDA action plan for rare neurodegenerative diseases.\"\n  ],\n  \"de_ai_title\": \"Verlängerung des Zugangs zu ALS-Therapien und Forschung bis 2031\",\n  \"de_summary\": \"Dieses Gesetz verlängert die Finanzierung der ALS-Forschung und den Zugang zu experimentellen Behandlungen bis 2031. Es soll die Entwicklung neuer Medikamente für Patienten mit ALS und anderen seltenen Nervenerkrankungen beschleunigen.\",\n  \"de_key_points\": [\n    \"Verlängerung der Forschungsgelder für ALS bis zum Jahr 2031.\",\n    \"Bessere Überwachung des Fortschritts klinischer Studien durch Datenaustausch.\",\n    \"Erweiterung der Definition klinischer Studien für schnelleren Therapiezugang.\",\n    \"Neuer FDA-Aktionsplan für seltene neurodegenerative Erkrankungen.\"\n  ],\n  \"fr_ai_title\": \"Prolongation de l'accès aux thérapies critiques contre la SLA jusqu'en 2031\",\n  \"fr_summary\": \"Cette loi prolonge le financement de la recherche sur la SLA et l'accès aux traitements expérimentaux jusqu'en 2031. Elle vise à accélérer le développement de nouveaux médicaments pour les patients atteints de maladies neurodégénératives rares.\",\n  \"fr_key_points\": [\n    \"Prolongation des subventions de recherche sur la SLA jusqu'en 2031.\",\n    \"Suivi renforcé des essais cliniques grâce au partage de données.\",\n    \"Élargissement de la définition des essais cliniques pour inclure plus d'études.\",\n    \"Nouveau plan d'action de la FDA pour les maladies neurodégénératives rares.\"\n  ],\n  \"es_ai_title\": \"Extensión del acceso a terapias críticas para la ELA hasta 2031\",\n  \"es_summary\": \"Esta ley extiende el financiamiento para la investigación de la ELA y el acceso a tratamientos experimentales hasta 2031. Busca acelerar el desarrollo de nuevas medicinas para pacientes con enfermedades neurodegenerativas raras.\",\n  \"es_key_points\": [\n    \"Extensión de las becas de investigación para la ELA hasta 2031.\",\n    \"Mayor control del progreso de los ensayos clínicos mediante el intercambio de datos.\",\n    \"Definición más amplia de ensayos clínicos para agilizar el acceso a terapias.\",\n    \"Nuevo plan de acción de la FDA para enfermedades neurodegenerativas raras.\"\n  ],\n  \"it_ai_title\": \"Estensione dell'accesso alle terapie critiche per la SLA fino al 2031\",\n  \"it_summary\": \"Questa legge prolunga i finanziamenti per la ricerca sulla SLA e l'accesso ai trattamenti sperimentali fino al 2031. L'obiettivo è velocizzare lo sviluppo di nuove cure per i pazienti affetti da malattie neurodegenerative rare.\",\n  \"it_key_points\": [\n    \"Proroga dei contributi per la ricerca sulla SLA fino al 2031.\",\n    \"Monitoraggio più stretto dei progressi dei test clinici.\",\n    \"Definizione ampliata di test clinici per facilitare l'accesso alle cure.\",\n    \"Nuovo piano d'azione della FDA per le malattie neurodegenerative rare.\"\n  ],\n  \"nl_ai_title\": \"Verlenging van toegang tot kritieke ALS-therapieën en onderzoek tot 2031\",\n  \"nl_summary\": \"Deze wet verlengt de financiering voor ALS-onderzoek en de toegang tot experimentele behandelingen tot 2031. Het doel is om de ontwikkeling van nieuwe medicijnen voor patiënten met zeldzame zenuwziekten te versnellen.\",\n  \"nl_key_points\": [\n    \"Verlenging van onderzoekssubsidies voor ALS tot 2031.\",\n    \"Beter toezicht op de voortgang van klinische studies.\",\n    \"Verruiming van de definitie van klinische studies voor snellere toegang.\",\n    \"Nieuw actieplan van de FDA voor zeldzame neurodegeneratieve ziekten.\"\n  ],\n  \"pt_ai_title\": \"Um novo título curto para o ato jurídico em português, capturando a essência das mudanças (por exemplo, máx. 10-12 palavras).\",\n  \"pt_summary\": \"Esta lei prolonga o financiamento para a investigação da ELA e o acesso a tratamentos experimentais até 2031. Visa acelerar o desenvolvimento de novos medicamentos para doentes com doenças neurodegenerativas raras.\",\n  \"pt_key_points\": [\n    \"Extensão das bolsas de investigação para a ELA até 2031.\",\n    \"Melhor acompanhamento do progresso dos ensaios clínicos.\",\n    \"Definição alargada de ensaios clínicos para agilizar o acesso a terapias.\",\n    \"Novo plano de ação da FDA para doenças neurodegenerativas raras.\"\n  ],\n  \"category\": [\n    \"Health\"\n  ]\n}"
    }
  ]
}